ABC | Volume 111, Nº2, August 2018

Original Article Duarte et al Iron impact in acute coronary syndrome Arq Bras Cardiol. 2018; 111(2):144-150 Ferritin tertile Ferritin tertile 1,0 0,8 0,6 0,4 0,2 0,0 Accumulated Survival Accumulated Survival Death_months 1 2 3 1 2 3 0 2 4 6 8 10 12 HF_months 1,0 0,8 0,6 0,4 0,2 p = 0,39 p = 0,62 0 5 10 15 20 Figure 3 – Survival curves according to ferritin tertiles. marker in ACS patients and establish the “actual” role of iron and ferritin in this type of cardiovascular disease. Author contributions Conception and design of the research: Duarte T, Gonçalves S; Acquisition of data: Duarte T, Sá C, Rodrigues R, Marinheiro R, Fonseca M; Analysis and interpretation of the data, statistical analysis and writing of the manuscript: Duarte T; Critical revision of the manuscript for intellectual content: Gonçalves S, Seixo F, Caria R. Potential Conflict of Interest No potential conflict of interest relevant to this article was reported. Sources of Funding There were no external funding sources for this study. Study Association This study is not associatedwith any thesis or dissertationwork. Ethics approval and consent to participate This article does not contain any studies with human participants or animals performed by any of the authors. 1. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives; Eur Heart J. 2013;34(11):816-29. 2. Fonseca C, Marques F, Robalo Nunes A, Belo A, Brilhante D, Cortez J. Prevalence of anaemia and iron deficiency in Portugal: the EMPIRE study. Intern Med J. 2016;46(4):470-8. 3. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al; ESC Scientific Document Group. 2016 ESCGuidelines for the diagnosis and treatment of acute and chronic heart failure; The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. 4. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11):657-68. 5. Dominguez-RodriguezA,Abreu-GonzalezP.Quantificationofserum ferritin in the acute coronary syndrome: a puzzle still to be resolved? Int J Cardiol. 2012;154(2):215. 6. Yalta K, Sivri N, Yalta T, Yetkin E. Serum ferritin: a potential determinant of myocardial ischemic burden in the setting of ischemic conditions? Int J Cardiol. 2011;153(2):225-6. 7. Basuli D, Stevens RG, Torti FM, Torti SV. Epidemiological associations between iron and cardiovascular disease and diabetes. Front Pharmacol. 2014 May 20;5:11. 8. Dominguez-RodriguezA,Carrillo-PerezTomeM,Hernandez-GarciaC,Arroyo- UcarE,Juarez-PreraR,Blanco-PalaciosG,etal.Serumferritinandacutecoronary syndrome:astrongprognosticfactor?IntJCardiol.2011;152(1):129-30. References 149